Eagle Veterinary Technology Co.Ltd
Eagle Veterinary Technology Co.,Ltd manufactures and sells animal health care products in South Korea. The company offers antibiotics, antibacterials, anthelmintics, antihistamins, and in the form of injectable, feed additives, oral liquids, and soluble powders for swine, poultry, and bovine. Eagle Veterinary Technology Co.,Ltd also exports its products to New Zealand, Australia, Vietnam, Kenya, … Read more
Eagle Veterinary Technology Co.Ltd (044960) - Net Assets
Latest net assets as of September 2025: ₩50.42 Billion KRW
Based on the latest financial reports, Eagle Veterinary Technology Co.Ltd (044960) has net assets worth ₩50.42 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩60.77 Billion) and total liabilities (₩10.35 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩50.42 Billion |
| % of Total Assets | 82.97% |
| Annual Growth Rate | 5.26% |
| 5-Year Change | 28.76% |
| 10-Year Change | 57.1% |
| Growth Volatility | 2.39 |
Eagle Veterinary Technology Co.Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Eagle Veterinary Technology Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eagle Veterinary Technology Co.Ltd (2014–2024)
The table below shows the annual net assets of Eagle Veterinary Technology Co.Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩48.59 Billion | +7.16% |
| 2023-12-31 | ₩45.34 Billion | +5.56% |
| 2022-12-31 | ₩42.95 Billion | +5.20% |
| 2021-12-31 | ₩40.83 Billion | +8.20% |
| 2020-12-31 | ₩37.74 Billion | +6.20% |
| 2019-12-31 | ₩35.53 Billion | +2.86% |
| 2018-12-31 | ₩34.55 Billion | +8.25% |
| 2017-12-31 | ₩31.91 Billion | +0.81% |
| 2016-12-31 | ₩31.66 Billion | +2.35% |
| 2015-12-31 | ₩30.93 Billion | +6.24% |
| 2014-12-31 | ₩29.11 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eagle Veterinary Technology Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 220.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩25.37 Billion | 52.22% |
| Common Stock | ₩6.32 Billion | 13.01% |
| Other Components | ₩16.90 Billion | 34.78% |
| Total Equity | ₩48.59 Billion | 100.00% |
Eagle Veterinary Technology Co.Ltd Competitors by Market Cap
The table below lists competitors of Eagle Veterinary Technology Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
$20.48 Million |
|
DENTA
NSE:DENTA
|
$20.49 Million |
|
BG Container Glass Public Company Limited
BK:BGC
|
$20.50 Million |
|
Innometry Co. Ltd
KQ:302430
|
$20.50 Million |
|
Klimasan Klima Sanayi ve Ticaret AS
IS:KLMSN
|
$20.47 Million |
|
Helport AI Limited Ordinary Shares
NASDAQ:HPAI
|
$20.47 Million |
|
Suprema HQ Inc
KQ:094840
|
$20.47 Million |
|
Yeh-Chiang Technology
TWO:6124
|
$20.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eagle Veterinary Technology Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 45,343,016,340 to 48,589,838,960, a change of 3,246,822,620 (7.2%).
- Net income of 3,705,275,820 contributed positively to equity growth.
- Dividend payments of 490,995,880 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.71 Billion | +7.63% |
| Dividends Paid | ₩491.00 Million | -1.01% |
| Other Changes | ₩32.54 Million | +0.07% |
| Total Change | ₩- | 7.16% |
Book Value vs Market Value Analysis
This analysis compares Eagle Veterinary Technology Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.44x to 1.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2751.02 | ₩3965.00 | x |
| 2017-12-31 | ₩2823.79 | ₩3965.00 | x |
| 2018-12-31 | ₩2814.38 | ₩3965.00 | x |
| 2019-12-31 | ₩2894.77 | ₩3965.00 | x |
| 2020-12-31 | ₩3074.19 | ₩3965.00 | x |
| 2021-12-31 | ₩3326.27 | ₩3965.00 | x |
| 2022-12-31 | ₩3499.36 | ₩3965.00 | x |
| 2023-12-31 | ₩3693.96 | ₩3965.00 | x |
| 2024-12-31 | ₩3958.47 | ₩3965.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eagle Veterinary Technology Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.88%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.26x
- Recent ROE (7.63%) is above the historical average (5.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 3.53% | 5.08% | 0.49x | 1.43x | ₩-1.88 Billion |
| 2015 | 3.34% | 4.12% | 0.57x | 1.42x | ₩-2.06 Billion |
| 2016 | 7.06% | 7.75% | 0.62x | 1.46x | ₩-931.53 Million |
| 2017 | 4.87% | 4.55% | 0.69x | 1.56x | ₩-1.64 Billion |
| 2018 | 3.02% | 3.44% | 0.66x | 1.33x | ₩-2.41 Billion |
| 2019 | 3.47% | 3.58% | 0.75x | 1.29x | ₩-2.32 Billion |
| 2020 | 6.52% | 6.09% | 0.83x | 1.28x | ₩-1.31 Billion |
| 2021 | 8.91% | 9.00% | 0.77x | 1.29x | ₩-445.12 Million |
| 2022 | 6.15% | 6.07% | 0.79x | 1.28x | ₩-1.65 Billion |
| 2023 | 6.56% | 6.95% | 0.73x | 1.29x | ₩-1.56 Billion |
| 2024 | 7.63% | 8.88% | 0.68x | 1.26x | ₩-1.15 Billion |
Industry Comparison
This section compares Eagle Veterinary Technology Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $102,348,386,998
- Average return on equity (ROE) among peers: -11.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eagle Veterinary Technology Co.Ltd (044960) | ₩50.42 Billion | 3.53% | 0.21x | $20.48 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |